Ingo Eitel1, Suzanne de Waha2, Jochen Wöhrle3, Georg Fuernau4, Phillipp Lurz4, Matthias Pauschinger5, Steffen Desch6, Gerhard Schuler4, Holger Thiele6. 1. Department of Internal Medicine-Cardiology, University of Leipzig-Heart Center, Leipzig, Germany; Department of Cardiology, Angiology, Intensive Care Medicine, University of Lübeck, Medical Clinic II, Lübeck, Germany. Electronic address: ingoeitel@gmx.de. 2. Department of Internal Medicine-Cardiology, University of Leipzig-Heart Center, Leipzig, Germany; Department of Cardiology, Heart Center Bad Segeberg, Bad Segeberg, Germany. 3. Department of Internal Medicine II-Cardiology, University of Ulm, Ulm, Germany. 4. Department of Internal Medicine-Cardiology, University of Leipzig-Heart Center, Leipzig, Germany. 5. Klinikum Nürnberg, Medizinische Klinik/Kardiologie, Nürnberg, Germany. 6. Department of Internal Medicine-Cardiology, University of Leipzig-Heart Center, Leipzig, Germany; Department of Cardiology, Angiology, Intensive Care Medicine, University of Lübeck, Medical Clinic II, Lübeck, Germany.
Abstract
BACKGROUND: Although the prognostic value of findings from cardiac magnetic resonance (CMR) imaging has been established in single-center center studies in patients with ST-segment elevation myocardial infarction (STEMI), a large multicenter investigation to evaluate the prognostic significance of myocardial damage and reperfusion injury is lacking. OBJECTIVES: The aim of this study was to assess the prognostic impact of CMR in an adequately powered multicenter study and to evaluate the most potent CMR predictor of hard clinical events in a STEMI population treated by primary percutaneous coronary intervention (PCI). METHODS: We enrolled 738 STEMI patients in this CMR study at 8 centers. The patients were reperfused by primary PCI <12 h after symptom onset. Central core laboratory-masked analyses for quantified left ventricular (LV) function, infarct size (IS), microvascular obstruction (MO), and myocardial salvage were performed. The primary clinical endpoint of the study was the occurrence of major adverse cardiac events. RESULTS: Patients with cardiovascular events had significantly larger infarcts (p < 0.001), less myocardial salvage (p = 0.01), a larger extent of MO (p = 0.009), and more pronounced LV dysfunction (p < 0.001). In a multivariate model that included clinical and other established prognostic parameters, MO remained the only significant predictor in addition to the TIMI (Thrombolysis In Myocardial Infarction) risk score. IS and MO provided an incremental prognostic value above clinical risk assessment and LV ejection fraction (c-index increase from 0.761 to 0.801; p = 0.036). CONCLUSIONS: In a large, multicenter STEMI population reperfused by primary PCI, CMR markers of myocardial damage (IS and especially MO) provide independent and incremental prognostic information in addition to clinical risk scores and LV ejection fraction. (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction [AIDA STEMI]; NCT00712101).
BACKGROUND: Although the prognostic value of findings from cardiac magnetic resonance (CMR) imaging has been established in single-center center studies in patients with ST-segment elevation myocardial infarction (STEMI), a large multicenter investigation to evaluate the prognostic significance of myocardial damage and reperfusion injury is lacking. OBJECTIVES: The aim of this study was to assess the prognostic impact of CMR in an adequately powered multicenter study and to evaluate the most potent CMR predictor of hard clinical events in a STEMI population treated by primary percutaneous coronary intervention (PCI). METHODS: We enrolled 738 STEMI patients in this CMR study at 8 centers. The patients were reperfused by primary PCI <12 h after symptom onset. Central core laboratory-masked analyses for quantified left ventricular (LV) function, infarct size (IS), microvascular obstruction (MO), and myocardial salvage were performed. The primary clinical endpoint of the study was the occurrence of major adverse cardiac events. RESULTS:Patients with cardiovascular events had significantly larger infarcts (p < 0.001), less myocardial salvage (p = 0.01), a larger extent of MO (p = 0.009), and more pronounced LV dysfunction (p < 0.001). In a multivariate model that included clinical and other established prognostic parameters, MO remained the only significant predictor in addition to the TIMI (Thrombolysis In Myocardial Infarction) risk score. IS and MO provided an incremental prognostic value above clinical risk assessment and LV ejection fraction (c-index increase from 0.761 to 0.801; p = 0.036). CONCLUSIONS: In a large, multicenter STEMI population reperfused by primary PCI, CMR markers of myocardial damage (IS and especially MO) provide independent and incremental prognostic information in addition to clinical risk scores and LV ejection fraction. (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction [AIDA STEMI]; NCT00712101).
Authors: Anthony A Holmes; Jorge Romero; Jeffrey M Levsky; Linda B Haramati; Newton Phuong; Leila Rezai-Gharai; Stuart Cohen; Lina Restrepo; Luis Ruiz-Guerrero; John D Fisher; Cynthia C Taub; Luigi Di Biase; Mario J Garcia Journal: J Interv Card Electrophysiol Date: 2017-11-15 Impact factor: 1.900
Authors: Derek J Hausenloy; William Chilian; Filippo Crea; Sean M Davidson; Peter Ferdinandy; David Garcia-Dorado; Niels van Royen; Rainer Schulz; Gerd Heusch Journal: Cardiovasc Res Date: 2019-06-01 Impact factor: 10.787
Authors: Nicola Galea; Gian Marco Dacquino; Rosa Maria Ammendola; Simona Coco; Luciano Agati; Laura De Luca; Iacopo Carbone; Francesco Fedele; Carlo Catalano; Marco Francone Journal: Eur Radiol Date: 2018-12-14 Impact factor: 5.315
Authors: Jiwon Kim; Sara Rodriguez-Diego; Aparna Srinivasan; Rachel-Maria Brown; Meridith P Pollie; Antonino Di Franco; Samantha R Goldburg; Jonathan Y Siden; Mark B Ratcliffe; Robert A Levine; Richard B Devereux; Jonathan W Weinsaft Journal: Echocardiography Date: 2017-08-22 Impact factor: 1.724
Authors: Gianluca Pontone; Patrizia Carità; Mark G Rabbat; Marco Guglielmo; Andrea Baggiano; Giuseppe Muscogiuri; Andrea I Guaricci Journal: Curr Cardiol Rep Date: 2017-08-31 Impact factor: 2.931